Yaozhong H. Zhao

Tianjin, 301600, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Journal: EClinicalMedicine

Published: August 15, 2025

Evaluation of the efficacy and safety of intravenous infusion of ferric derisomaltose in the treatment of iron deficiency anemia: a single-center retrospective analysis

Evaluation of the efficacy and safety of intravenous infusion of ferric derisomaltose in the treatment of iron deficiency anemia: a single-center retrospective analysis

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: April 11, 2024

Clinical characteristics and prognosis of 21 patients with thymoma-associated pure red cell aplasia

Clinical characteristics and prognosis of 21 patients with thymoma-associated pure red cell aplasia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: March 19, 2024

Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.

Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.

Journal: Cancer medicine

Published: November 06, 2023

The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.

The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.

Journal: Hematology (Amsterdam, Netherlands)

Published: September 19, 2023

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.

Journal: BMC cancer

Published: April 12, 2023

A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.

A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.

Journal: Bone marrow transplantation

Published: October 11, 2021

Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial.

Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial.

Journal: Investigational new drugs

Published: September 16, 2021

Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study.

Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study.

Journal: International journal of cancer

Published: July 21, 2021

Pro-angiogenic effect of exosomal microRNA-103a in mice with rheumatoid arthritis via the downregulation of hepatocyte nuclear factor 4 alpha and activation of the JAK/STAT3 signaling pathway.

Pro-angiogenic effect of exosomal microRNA-103a in mice with rheumatoid arthritis via the downregulation of hepatocyte nuclear factor 4 alpha and activation of the JAK/STAT3 signaling pathway.

Journal: Journal of biological regulators and homeostatic agents

Published: April 23, 2021

1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib.

1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib.

Journal: Leukemia & lymphoma

Published: December 18, 2019

Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma.

Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma.

Journal: Leukemia

Published: June 11, 2019

Showing 1-12 of 33

Last Updated: 09/26/2026